Tucidinostat is a subtype-selective histone deacetylase inhibitor (HDACi), which is a new generation of epigenetic modulator by selectively inhibiting HDACs 1, 2, 3, and 10 isoforms, and is a well-known new targeted anti-cancer drug. Tucidinostat has been licensed the patent right and market right of Taiwan to GNTbm by originator Chipscreen Biosciences in September 2013, and GNTbm has led the development of a number of clinical trials and domestic manufacture of API and drug product in Taiwan.